Breakthrough in Snakebite Treatment!

Snakebite Treatment: Published in Cell, a groundbreaking study reports a universal antivenom strategy using a 3-agent cocktail—two broadly neutralizing human antibodies plus varespladib—that protected against venom from 19 deadly snake species across 10 genera in the Elapidae family.

🔬 Key Highlights:
• Broadly neutralizing antibodies were isolated from a hyperimmune human exposed to multiple venoms
• These antibodies mimic the snake toxin’s target (nAChR) and block its function
• The cocktail neutralizes major neurotoxins (LNXs, SNXs) and enzymatic toxins (PLA2s)
• Potential to become the first human-derived universal antivenom, offering:

1. Broader protection across species
2. Reduced risk of serum sickness
3. Longer half-life and improved safety
4. Easier stockpiling and distribution

🌍 A universal antivenom could save over 100,000 lives/year, especially in regions lacking species-specific antivenoms. It also opens the door for recombinant antibody-based solutions for Viperidae and other toxin families.

📉 Limitations: Current findings are based on mouse models and standard venom doses; real-world efficacy in humans and high-dose bites still requires further validation.

This is a promising leap toward solving a long-standing neglected tropical disease and improving global health equity.

Source on Snakebite: https://www.cell.com/cell/fulltext/S0092-8674%2825%2900402-7

#Antivenom #Snakebite #CellPress #Immunotherapy #Varespladib #Antibodies #GlobalHealth #NeglectedDiseases #Elapidae #InnovationInBiotech

Check this scholarship: https://biopatrika.com/career/award-fellowship-grant/azim-premji-scholarship-for-girls/